Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Science 13 June 1986:
Vol. 232. no. 4756, pp. 1367 - 1372
DOI: 10.1126/science.232.4756.1367

Articles

Biotechnology in Europe

MARK D. DIBNER 1

1 Neurobiologist in the Central Research and Development Department, E. I. du Pont de Nemours & Company, Experimental Station E400, Wilmington, DE 19898, and a senior fellow in the Management and Technology Program of the Wharton School at the University of Pennsylvania.

The countries of the European Economic Community have recently mounted considerable efforts to commercialize biotechnology. Together, these efforts approach the same number of companies and level of government spending as those in the United States. In Europe there is more government emphasis on support for industry-university collaborations and industrial projects than in the United States, where basic research is emphasized. European efforts are often not easily delineated from those in the United States; many European companies have extensive U.S. operations and many U.S. companies have involvement in Europe. Strategies and efforts in European biotechnology are examined and compared to those in the United States.





To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)